这项第三期研究将评估研究药物 MRTX849 (adagrasib) 对比 docetaxel 在既往接受过治疗、带有 KRAS G12C 突变的转移性 NSCLC 患者中的疗效。
适应症：Metastatic Non Small Cell Lung Cancer、Advanced Non Small Cell Lung Cancer
入组条件
纳入标准
- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
- Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- ECOG performance status 0-2
排除标准
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
- Active brain metastases.
- Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。